Retatrutide, a novel dual stimulator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising outcomes in preliminary clinical studies. Current https://bouchesocial.com/story23629050/retatrutide-emerging-studies-and-projected-therapeutic-uses